Cognition Therapeutics, Inc. CGTX

October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology has been scheduled for October 20, 2026. The objective

PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s president and CEO. “Discussions with th

Recently published Dementia-related Psychosis Market Insights report includes a comprehensive understanding of current treatment practices, dementia-related psychosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

Cognition Therapeutics (NASDAQ:CGTX) shares gained 5% after the company announced that it had received written feedback from the U. S.

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) following its r

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468. The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent w

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Cognition Therapeutics, Inc. (NASDAQ:CGTX) is one of the most popular penny stocks on Robinhood. TheFly reported on May 21 that CGTX held a planned regulatory meeting with the U.S. Food and Drug Administration to review Phase 2 results […]

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations

- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The objective of this meeting was to review results from the Phase 2 study of zervimesine

PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new don

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit from an infected person and incidents are becoming more common on cruises, making a global […]

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We filed a request to meet with the

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diwan, PhD, will offer one-on-one meetings on the same day from 9:45AM to 2:45PM ET. […]